Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

Literature DB >> 3838637

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

Abstract

BMY-28142 was compared with other broad-spectrum antibiotics against gram-positive cocci and gram-negative bacilli. BMY-28142 was highly active against all gram-negative bacilli and especially against Enterobacter cloacae, Serratia marcescens, and Morganella morganii. Its in vitro activity suggests that BMY-28142 should prove to be useful for the treatment of gram-negative bacillary infections.

Entities: Chemical Species

Mesh：

Substances：

Year: 1985 PMID： 3838637 PMCID： PMC176251 DOI： 10.1128/AAC.27.2.265

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

4 in total

Review 1. The new beta-lactamase-stable cephalosporins.

Authors: H C Neu
Journal: Ann Intern Med Date: 1982-09 Impact factor: 25.391

2. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients.

Authors: V Fainstein; G P Bodey; R Bolivar; L Elting; K B McCredie; M J Keating
Journal: Arch Intern Med Date: 1984-09

3. Activity of beta-lactamase inhibitors in combination with new beta-lactam antibiotics against resistant gram-negative organisms.

Authors: R Bolivar; S S Weaver; G P Bodey
Journal: Diagn Microbiol Infect Dis Date: 1984-06 Impact factor: 2.803

4. Comparative in vitro study in new cephalosporins.

Authors: G P Bodey; V Fainstein; A M Hinkle
Journal: Antimicrob Agents Chemother Date: 1981-08 Impact factor: 5.191

4 in total

13 in total

1. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.

Authors: S K Spangler; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1994-04 Impact factor: 5.191

2. Open trial of cefepime (BMY 28142) for infections in hospitalized patients.

Authors: S Oster; H Edelstein; K Cassano; R McCabe
Journal: Antimicrob Agents Chemother Date: 1990-06 Impact factor: 5.191

3. Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci.

Authors: K S Kim; A S Bayer
Journal: Antimicrob Agents Chemother Date: 1985-07 Impact factor: 5.191

4. In vitro activity of DQ-2556, a new cephalosporin.

Authors: T Fujimoto; T Otani; R Nakajima; T Une; Y Osada
Journal: Antimicrob Agents Chemother Date: 1986-10 Impact factor: 5.191

Review 5. Cefepime clinical pharmacokinetics.

Authors: M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal: Clin Pharmacokinet Date: 1993-08 Impact factor: 6.447

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

Review 1. The new beta-lactamase-stable cephalosporins.

2. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients.

3. Activity of beta-lactamase inhibitors in combination with new beta-lactam antibiotics against resistant gram-negative organisms.

4. Comparative in vitro study in new cephalosporins.

1. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.

2. Open trial of cefepime (BMY 28142) for infections in hospitalized patients.

3. Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci.

4. In vitro activity of DQ-2556, a new cephalosporin.

Review 5. Cefepime clinical pharmacokinetics.

6. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.

7. Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats.

8. Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria.

9. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.

10. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.